KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Non Operating Income (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Non Operating Income for 15 consecutive years, with $138.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income rose 300.45% year-over-year to $138.2 million, compared with a TTM value of $11.2 million through Dec 2025, up 106.25%, and an annual FY2025 reading of $5.2 million, up 102.88% over the prior year.
  • Non Operating Income was $138.2 million for Q4 2025 at Alnylam Pharmaceuticals, up from -$87.4 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $138.2 million in Q4 2025 and bottomed at -$221.0 million in Q4 2022.
  • Average Non Operating Income over 5 years is -$47.0 million, with a median of -$43.3 million recorded in 2021.
  • The sharpest move saw Non Operating Income surged 3082.32% in 2021, then tumbled 6218.33% in 2024.
  • Year by year, Non Operating Income stood at -$65.7 million in 2021, then tumbled by 236.24% to -$221.0 million in 2022, then soared by 99.51% to -$1.1 million in 2023, then crashed by 6218.33% to -$68.9 million in 2024, then skyrocketed by 300.45% to $138.2 million in 2025.
  • Business Quant data shows Non Operating Income for ALNY at $138.2 million in Q4 2025, -$87.4 million in Q3 2025, and -$19.2 million in Q2 2025.